VEGFA and cancer: AMD is characterised by the over expression of VEGF which causes angiogenesis in the back of the eye resulting in loss of retinal function.27 Bevacizumab is an IgG that is targeted to VEGF, but is labelled for systemic parenteral use to treat cancer.